Drug

FDA Approves Priovant's LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication
Priovant TherapeuticsProduct approvals

FDA Approves Priovant’s LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication

The U.S. Food and Drug Administration (FDA) has approved LISRAYA (brepocitinib) 30 mg tablets, developed by Priovant Therapeutics (a Roivant Sciences / Pfizer venture), for the treatment of adult dermatomyositis…

AnnJi Advances AJ201 into Pivotal Phase 3 ROMA‑KD Trial – The Only Investigational Therapy for SBMA in Late‑Stage Development Worldwide

AnnJi Advances AJ201 into Pivotal Phase 3 ROMA‑KD Trial – The Only Investigational Therapy for SBMA in Late‑Stage Development Worldwide

Pfizer's Oral Ritlecitinib Meets Primary Endpoints in Phase III Nonsegmental Vitiligo Trials – Largest‑Ever Oral Systemic Program Clears Path for Global Filings

Pfizer’s Oral Ritlecitinib Meets Primary Endpoints in Phase III Nonsegmental Vitiligo Trials – Largest‑Ever Oral Systemic Program Clears Path for Global Filings

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CancerClinical trial approval / initiation

LTZ Therapeutics Secures FDA IND Approval for LTZ-232, First-in-Class Myeloid Engager Targeting EpCAM-High Solid Tumors

Shanghai Stexo Biotechnology Secures NMPA Clinical Approval for STX11101 Extracellular Vesicle Therapy in Acute Liver Failure
Clinical trial approval / initiationStexo Biotechnology

Shanghai Stexo Biotechnology Secures NMPA Clinical Approval for STX11101 Extracellular Vesicle Therapy in Acute Liver Failure

CDENMPA

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

HKG: 1177Market approval filings

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Show More